CARsgen Therapeutics (HKG:2171) obtained approval for the new drug application of satricabtagene autoleucel from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
The drug was approved for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma.